Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

George A, Tam CS, Seymour JF.

Leuk Lymphoma. 2013 Dec;54(12):2575-6. doi: 10.3109/10428194.2013.796059. Epub 2013 May 21. No abstract available.

PMID:
23597141
2.

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.

Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M.

Leuk Lymphoma. 2012 Nov;53(11):2290-2. doi: 10.3109/10428194.2012.682311. Epub 2012 May 22. No abstract available.

PMID:
22475324
3.

TP53 mutations and rituximab-CHOP.

Gisselbrecht C.

Blood. 2012 Nov 8;120(19):3867-9. doi: 10.1182/blood-2012-09-455865. No abstract available.

4.

Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?

Mondello P, Cuzzocrea S, Pitini V, Aloisi C, Mian M.

Acta Oncol. 2015 Jun;54(6):953-5. doi: 10.3109/0284186X.2015.1027410. Epub 2015 Apr 1. No abstract available.

PMID:
25831143
5.

CD30, another useful predictor of survival in DLBCL?

Chan WC.

Blood. 2013 Apr 4;121(14):2582-3. doi: 10.1182/blood-2013-02-481978. No abstract available.

6.

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.

Mato A, Feldman T, Zielonka T, Singavi A, Gadaletta G, Waksmundzki K, Bhattacharyya P, Chow KF, Yang X, Panush D, Agress H, Rosario M, Howlett C, Pecora A, Goy A.

Leuk Lymphoma. 2013 Dec;54(12):2606-12. doi: 10.3109/10428194.2013.783909. Epub 2013 May 15.

PMID:
23488604
7.

There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.

Wendtner CM.

Leuk Lymphoma. 2013 Nov;54(11):2343-4. doi: 10.3109/10428194.2013.807513. Epub 2013 Jul 16. No abstract available.

PMID:
23725391
8.

Chemo-immunotherapy dosing in older patients with diffuse large B-cell lymphoma: is this how we should treat our parents?

Link BK.

Leuk Lymphoma. 2012 Aug;53(8):1435-6. doi: 10.3109/10428194.2012.672737. Epub 2012 Apr 2. No abstract available.

PMID:
22397718
9.

Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.

Rund D.

Leuk Lymphoma. 2014 Sep;55(9):1966-7. doi: 10.3109/10428194.2014.898762. Epub 2014 Mar 25. No abstract available.

PMID:
24588736
10.

Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.

Ribera JM, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, Navarro JT, Feliu E.

Br J Haematol. 2012 Jun;157(5):637-9. doi: 10.1111/j.1365-2141.2012.09046.x. Epub 2012 Feb 7. No abstract available.

PMID:
22313456
11.

CHOP plus rituximab--balancing facts and opinion.

Cheson BD.

N Engl J Med. 2002 Jan 24;346(4):280-2. No abstract available.

PMID:
11807154
12.

Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.

Pfreundschuh M.

J Clin Oncol. 2012 Oct 1;30(28):3433-5. Epub 2012 Sep 4. No abstract available.

PMID:
22949148
13.

R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.

Fowler NH.

Clin Adv Hematol Oncol. 2014 Sep;12(9):608-10. No abstract available.

PMID:
25654483
14.

Double-hit diffuse large B-cell lymphoma.

Friedberg JW.

J Clin Oncol. 2012 Oct 1;30(28):3439-43. Epub 2012 Sep 4. No abstract available.

PMID:
22949152
15.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C.

N Engl J Med. 2002 Jan 24;346(4):235-42.

16.

TP53 and outcome in DLBCL: not only the coding region.

Jardin F, Coiffier B.

Blood. 2013 May 30;121(22):4433-4. doi: 10.1182/blood-2013-04-493486.

17.

Elevated soluble CD 27 levels (TNF-receptor) may predict survival in diffuse large B-cell lymphoma--revisiting "the super- family " saga.

Tadmor T, Polliack A.

Leuk Lymphoma. 2012 Aug;53(8):1439-40. doi: 10.3109/10428194.2012.666546. Epub 2012 Mar 13. No abstract available.

PMID:
22335528
18.

Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.

Lai S, Venugopal P, Leslie W.

Clin Adv Hematol Oncol. 2012 Feb;10(2):134-6. No abstract available.

PMID:
22402359
19.

Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.

Coiffier B, Salles G.

Blood. 2004 Sep 1;104(5):1584-5; author reply 1585-6. No abstract available.

20.

A blind skin biopsy diagnosing an intravascular large B-cell lymphoma.

Deschamps L, Signate A, Delaunay C, Morales I, Warter A, Smadja D, Derancourt C.

Eur J Dermatol. 2011 Jan-Feb;21(1):114-5. doi: 10.1684/ejd.2010.1174. No abstract available.

PMID:
21233067

Supplemental Content

Support Center